SAN DIEGO — Patients with COPD treated with targeted lung denervation along with optimal COPD therapy experienced fewer exacerbations over 2 years, according to research presented at the American Thoracic Society International Conference.Targeted lung denervation (Nuvaira Inc.) has “only [been] done in research setting to date,” Gerard J. Criner, MD, FACP, FACCP, chair and
/PRNewswire/ ViewRay, Inc. (NASDAQ: VRAY) announced today that the findings from the first Phase II prospective international multi-institutional study to.
/PRNewswire/ Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announces two treatment milestones. 200 patients have.
/PRNewswire/ Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announces two treatment milestones. 200 patients have.